Research contributes to revised decision on availability of Alzheimer's drugs

Jan 18, 2011

A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced today (18th January 2011).

A previous appraisal by NICE of these drugs in 2004 approved the use of donepezil, galantamine and rivastigmine for people with moderate , while the use of was restricted to .

As part of its ongoing review of its previous decisions, NICE requested a review of new evidence which was carried out by PenTAG, which is independent of NICE.

The evidence showed that little had changed and that all the drugs had some effect on delaying symptom progression in Alzheimer's. PenTAG also noted the uncertainty surrounding the estimates used in the previous economic model and hence its results. A new developed by PenTAG and which was calibrated differently to the model used in the previous assessment, showed the drugs to be cost-effective, although some uncertainty remains.

As a consequence, the report from PenTAG was a key piece of evidence that has informed the decision by NICE's appraisal committee to extend the availability of donepezil, galantamine and rivastigmine to people with mild Alzheimer's disease, and memantine to those with severe forms of the disease.

Professor Chris Hyde from PenTAG commented: "Alzheimer's disease and are a growing problem for the UK. The Alzheimer's Society estimates that there are 750,000 people with dementia in the UK today, and that this figure will grow to over one million by 2025. The costs associated with the disease are huge, with over 60,000 deaths attributed to dementia and a national financial cost to the country of £20 billion. Our work for NICE allows a rigorous and independent re-assessment of the balance of research evidence for additional patient benefits against the extra costs to the NHS of providing different treatments."

Explore further: Nigeria confirms Liberian man died of Ebola in Lagos (Update)

Provided by The Peninsula College of Medicine and Dentistry

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Drugs may not delay onset of dementia; and more

Nov 27, 2007

Researchers have examined the evidence in favour of giving people considered to be close to developing dementia the drugs that are most commonly used to treat the condition itself. They have concluded that these drugs (cholinesterase ...

Guidance on preventing unintentional injuries to children

Dec 13, 2010

Researchers from the Peninsula Technology Assessment Group (PenTAG) at the Peninsula College of Medicine and Dentistry have contributed to new National Institute for Health and Clinical Excellence (NICE) guidance on preventing ...

Link identified between Alzheimer's disease and glaucoma

Aug 06, 2007

UK scientists have shown for the first time that key proteins involved in Alzheimer's disease are also implicated in glaucoma, the major cause of irreversible blindness worldwide. Research carried out at the UCL Institute ...

Recommended for you

Chicken off McDonald's HK menu after food scandal

Jul 25, 2014

(AP)—McDonald's restaurants in Hong Kong have taken chicken nuggets and chicken filet burgers off the menu after a mainland Chinese supplier was accused of selling expired meat.

User comments : 0